Risk Factors of Porphyria Cutanea Tarda (PCT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00213772|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : September 21, 2005
Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.
Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen decarboxylase activity, HCV genotye, history of disease.
|Condition or disease|
|Porphyria Cutanea Tarda|
|Study Type :||Observational|
|Estimated Enrollment :||280 participants|
|Observational Model:||Case Control|
|Official Title:||“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”|
|Study Start Date :||May 1999|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213772
|Principal Investigator:||Bernard Cribier, MD||Hopitaux Universitaires de Strasbourg|
|Principal Investigator:||O. Chosidow, MD||Hopital Pitié-Salpétrière / Paris|
|Principal Investigator:||M. Bagot, MD||Hopital Henri Mondor / CHU Créteil|
|Principal Investigator:||J.P Lacour, MD||Hopital de l'Archet / CHU Nice|